Preprint · OA
via OpenAlex
Proteostasis mechanisms in direct neuronal reprogramming
Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · 2026
Abstract
Despite significant progress in the field of direct neuronal reprogramming, there are still many challenges that need to be addressed prior to clinical application. A deeper understanding of the mechanisms driving fate conversion, as well as the specific hurdles that hinder this process, is essential to optimize conversion efficiency and enable the application of neuronal reprogramming as a therapeutic strategy. The focus of my PhD thesis was to address these hurdles and determine their impact on direct neuronal reprogramming focusing on mitochondrial dysfunction(definition), impairments in proteostasis(definition) and protein aggregation. Overall, I aimed to understand the involvement of different proteostasis mechanisms during direct neuronal reprogramming, when many new proteins have to be made to install the new cell fate and others have to be degraded to abolish the glia-specific proteins. This is relevant for reprogramming of healthy cells, but even more so in neurodegenerative diseases with protein aggregate loads to probe and further develop this approach as a viable therapeutic intervention in chronic disease. Following the finding that mitochondrial dysfunction poses a major hurdle in mouse astrocyte to neuron conversion, we determined the impact of mitochondrial dysfunction in the reprogramming of human cells by generating proliferating astrocytes from patient iPSCs carrying mutations in the NDUFS4 gene as a model for Complex I dysfunction. Pharmacological targeting of distinct aspects of mitochondrial function and ER stress allowed us to identify the unfolded protein response (UPR) as a novel, general hurdle in direct neuronal reprogramming. Specifically, we propose ER-stress mediated inhibition of translation by the PERK pathway as a critical hurdle in the early stages of neuronal conversion. Importantly, we demonstrated that pharmacological inhibition of the UPR significantly improves the neuronal conversion of both control and patient astrocytes, suggesting its potential to facilitate neuronal conversion in health and disease. Moreover, we determined that protein synthesis levels increase during direct neuronal reprogramming, leading to an accumulation of misfolded proteins and eventual activation of the UPR. Altogether, this work highlights the key importance of proteostasis during early stages of neuronal conversion and suggests that processes like translation, protein folding and UPR activation act as major hurdles in the neuronal reprogramming of human cells. Given the implication of proteostasis mechanisms in direct neuronal reprogramming, it then became crucial to explore this strategy in a disease model where protein homeostasis is disrupted, as is the case in most neurodegenerative diseases. Using a mouse model of ALS recapitulating C9orf72 pathology, we determined that protein aggregation and impaired proteasome function significantly decrease neuronal conversion. While we propose strategies to overcome these limitations, their success may be limited by the stage of disease progression. Pharmacological modulation of proteasomal activity resulted in only mild improvements in the reprogramming of transgenic astrocytes, with aggregate load remaining unchanged. Notably, promoting protein degradation to prevent protein misfolding in healthy human astrocytes did not improve reprogramming efficiency, suggesting a complex interplay between protein quality control mechanisms and cell fate conversion. In summary, my PhD aimed to unravel key hurdles in direct neuronal reprogramming, particularly those arising from chronic disease states. This thesis proposes proteostasis mechanisms as a bottleneck for direct neuronal reprogramming and provides insights into how current strategies could be optimized to apply direct neuronal reprogramming as a viable therapeutic strategy for chronic and neurodegenerative diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.5282/edoc.36827
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Malpartida, A.B. (2026). Proteostasis mechanisms in direct neuronal reprogramming. <em>Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)</em>. https://doi.org/10.5282/edoc.36827
Vancouver
Malpartida AB. Proteostasis mechanisms in direct neuronal reprogramming. Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München). 2026. doi:10.5282/edoc.36827.
BibTeX
@unpublished{ana2026Proteo,
title = {Proteostasis mechanisms in direct neuronal reprogramming},
author = {Ana Belén Malpartida},
journal = {Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)},
year = {2026},
doi = {10.5282/edoc.36827},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Cell and Developmental Biology 2024
Open access · CC-BY
Next-generation direct reprogramming
Neural Regeneration Research 2019
Open access · CC-BY
Induced pluripotent stem cells from Huntington’s disease patients: a promising approach to define and correct disease-related alterations
Annual Review of Biochemistry 2009
Citation only
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
FEBS Journal 2018
Open access · CC-BY
The unfolded protein response in neurodegenerative disorders – therapeutic modulation of the PERK pathway
Frontiers in Physiology 2014
Open access · CC-BY
Bcl-xL in neuroprotection and plasticity
Biology of the Cell 2019
Preprint · CC-BY